

:

1

• •

« »

(11, 12, 15, 16).

14).

(12).

» (9, 19).

(BETA),
(8)

CATIE (8).

291

(18).

(STAR),

26-

¹
Myers Squibb.

Bristol-

98

12

« » 59% ; -
 LOCF. 30% 58% 30%
 IAQ, CGI-S, CGI-I -
 LOCF (ANCOVA). -
 BETA 46% 42% -
 70% - QLS 8, 18 26-
 4,3±1,1 4,3±1,0 (p<0,01÷0,001) 4 -
 STAR : 66,5% BETA 72% -
 63,5% ; 10,9% 13,3% (p<0,01÷0,001) 64% 5% -
 - ; 13,0% 10,0% -) (24%
 CGI 8- 3,65 3,78 (BETA) -), (11% 8% 6% -
 (LOCF) - 103,4 / , (10%), (7%), (6%)
 19,9 / , - 352,0 (6%).
 - 3,4 / , - 13,9 / .
 STAR :
 - 18,7 / , - 12,5 / ,
 - 386,8 / , - 4,6 / .
 8- (18) , 8% 10% ,
 CGI- (2,77), (5% 3% -
 7 4 3,3% 3,4% -
 () 1% -
 - 54-69% (-
 STAR (6).
 30,9-37,6% 77% ,
 26- (6) , 71% -
 IAQ (24,1%), (16,0%), (5,0%);
 (25,7 27,7 , p<0,001), (13,5%), (10,6%), (11,7%),
 (11,3%), - (9,4%),
 4- (7,9%), (7,5%),
 (6,0%).
 IAQ , « » « (13,5% 5,6% - 8,9% 2,3%).
 », (80 81 -
 () , 26- (62% 0,9 -
 10%) « » (49% 36%), (0,7%),
 49% « » (35% 23%), « -
 « » (54% 43%), « » (65% -
 49%) (56% 43%). CGI- 21,2% 7,3% 15,8% -
 (p=0,009).
 (POM) - 7% (-
 - 9,1%).

59,7%) (39,1% 60,0%), (47,8% 70,2%).
16,8% (52,9%)

(54,4%).

(18).

1. Casey D.E., Carson W.H., Saha A.R. et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study // *Psychopharmacology*. – 2003. – Vol. 166. – P. 391–399.
2. EuroQoL Group. EuroQoL – a new facility for the measurement of health-related quality of life // *Health Policy*. – 1990. – Vol. 16. – P. 199–208.
3. Heinrichs D.W., Hanlon T.E., Carpenter Jr.W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome // *Schizophr. Bull.* – 1984. – Vol. 10. – P. 388–398.
4. Kane J.M., Carson W.H., Saha A.R. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder // *J. Clin. Psychiatry*. – 2002. – Vol. 63, N 9. – P. 763–771.
5. Kasper S., Lerman M.N., McQuade R.D. et al. Efficacy and safety of aripiprazole versus haloperidol for long-term maintenance treatment following acute relapse of schizophrenia // *Int. J. Psychopharmacol.* – 2003. – Vol. 6. – P. 325–337.
6. Kerwin R., Millet B., Herman E. et al. A multicenter, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study // *Eur. Psychiatry*. – 2007. – Vol. 22, N 7. – P. 433–443.
7. Kolotkin R.L., Crosby R.D., Kosloski K.D., Williams G.R. Development of brief measure to assess quality of life in obesity // *Obes. Res.* – 2001. – Vol. 9. – P. 102–111.
8. Lieberman J.A., Stroup T.S., McEvoy J.P. et al. Effectiveness of antipsychotic drugs in patient with chronic schizophrenia // *N. Engl. J. Med.* – 2005. – Vol. 353. – P. 1209–1223.
9. Mahmoud R., Engelhart L., Janagap C. et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorders // *Clin. Drug Invest.* – 2004. – Vol. 25. – P. 275–286.
10. Marder S.R., McQuade R.D., Stock E. et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials // *Schizophr. Res.* – 2003. – Vol. 61. – P. 123–136.

11. Moller H.-J. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences // *World J. Biol. Psychiatry*. – 2000. – Vol. 1. – P. 75–91.
12. Nasrallah H.H., Targum S.D., Tandon R. et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia // *Psychiatr. Serv.* – 2005. – Vol. 56. – P. 273–282.
13. Pigott T.A., Carson W.H., Saha A.R. et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study // *J. Clin. Psychiatry*. – 2003. – Vol. 64, N 9. – P. 1048–1056.
14. Potkin S.G., Saha A.R., Kujava M.J. et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder // *Arch. Gen. Psychiatry*. – 2003. – Vol. 60, Jul. – P. 391–399.
15. Tandon R., Fleischhacker W.W. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment // *Schizophr. Res.* – 2005. – Vol. 79. – P. 145–155.
16. Tandon R., Jibson M.D. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole // *Int. J. Psychiatr. Clin. Pract.* – 2005. – Vol. 9. – P. 267–275.
17. Tandon R., Devellis R.F., Han J. et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for the relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder // *Psychiatr. Res.* – 2005. – Vol. 136. – P. 211–221.
18. Tandon R., Marcus R.N., Stock E.G. et al. A prospective, multicenter, randomized, parallel group, open-label study aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA) // *Schizophr. Res.* – 2006. – Vol. 84. – P. 77–89.
19. Weiden P.J., Aquila R., Dalheim L. et al. Switching antipsychotic medication // *J. Clin. Psychiatry*. – 1997. – Vol. 58, Suppl. 10. – P. 63–72.